Journey Medical (DERM)
(Delayed Data from NSDQ)
$3.41 USD
-0.09 (-2.50%)
Updated Apr 26, 2024 12:49 PM ET
3-Hold of 5 3
B Value B Growth F Momentum B VGM
Income Statements
Fiscal Year end for Journey Medical Corporation falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 79 | 74 | 63 | 45 | 35 |
Cost Of Goods | 27 | 31 | 32 | 15 | 11 |
Gross Profit | 53 | 43 | 31 | 30 | 24 |
Selling & Adminstrative & Depr. & Amort Expenses | 55 | 70 | 66 | 22 | 19 |
Income After Depreciation & Amortization | -2 | -28 | -35 | 8 | 5 |
Non-Operating Income | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 2 | 2 | 7 | 1 | 0 |
Pretax Income | -4 | -30 | -42 | 7 | 5 |
Income Taxes | 0 | 0 | 2 | 2 | 1 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -4 | -30 | -44 | 5 | 4 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -4 | -30 | -44 | 5 | 4 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 5 | -23 | -30 | 9 | 7 |
Depreciation & Amortization (Cash Flow) | 7 | 4 | 5 | 2 | 1 |
Income After Depreciation & Amortization | -2 | -28 | -35 | 8 | 5 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 18.23 | 17.53 | 10.19 | NA | NA |
Diluted EPS Before Non-Recurring Items | -0.21 | -1.69 | -4.32 | NA | NA |
Diluted Net EPS (GAAP) | -0.21 | -1.69 | -4.32 | 0.49 | NA |
Fiscal Year end for Journey Medical Corporation falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 15.26 | 34.54 | 17.17 | 12.21 |
Cost Of Goods | NA | 6.01 | 6.43 | 7.77 | 6.45 |
Gross Profit | NA | 9.24 | 28.11 | 9.41 | 5.76 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 11.35 | 10.87 | 17.05 | 15.32 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -2.11 | 17.24 | -7.64 | -9.56 |
Non-Operating Income | NA | 0.11 | -0.09 | 0.05 | 0.08 |
Interest Expense | NA | 0.02 | 0.27 | 0.76 | 0.65 |
Pretax Income | NA | -2.02 | 16.88 | -8.36 | -10.14 |
Income Taxes | NA | 0.13 | 0.10 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -2.14 | 16.79 | -8.36 | -10.14 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -2.14 | 16.79 | -8.36 | -10.14 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 18.23 | 21.04 | 18.01 | 17.81 |
Diluted EPS Before Non-Recurring Items | NA | -0.12 | 0.80 | -0.46 | -0.57 |
Diluted Net EPS (GAAP) | NA | 0.02 | 0.80 | -0.46 | -0.57 |